Sprint Nextel Corp. (NYSE: S) just continues to have one bad news release after another. The third-largest wireless carrier in the U.S. reported a dismal Q1 period, as a $211 million loss was posted amid large investments in operations that erased modest sales gains. At the same time, Sprint lost "high-quality subscribers" to the competition as problems with the Nextel side of the business continued.
Since Sprint acquired Nextel in 2005, the two businesses have not been integrated successfully. Before the merger, the ARPU (average revenue per user) for Nextel wireless subscribers was the highest in the entire U.S. wireless industry. After the merger, apparently Sprint did not take the steps needed to keep Nextel subscribers happy, the Nextel network deteriorated and massive defections resulted.
Sprint's loss of $211 million came to 7 cents per share, versus a profit available to common shareholders of $417 million, or 14 cents per share, a year ago. Q1 revenues were $10.1 billion (up from $10.07 billion a year ago), but CEO Gary Forsee stated that Sprint had spent a lot of money during the quarter trying to alleviate technological and signal problems that have driven away customers from its press-to-talk service.
Is it too little, too late to salvage the loyal Nextel subscriber? Possibly. If that ends up being the case, the incompetence Sprint management displayed after the Nextel acquisition should cause some heads to roll. I'm surprised it hasn't happened already, to be honest. The two leading wireless carriers in the U.S., Cingular Wireless (now AT&T Inc. (NYSE: T)) and Verizon Wireless (Verizon Communications (NYSE: VZ)), have benefited from Sprint's missteps in a huge way.
Last updated: February 09, 2012: 11:55 PM
Hot Stocks
DailyFinance Headlines
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
- Why Used Car Bargains Are Getting Harder to Find
- 5 Reasons Facebook Stock May Be a Better Buy Than You Think
- Department Stores Reveal Top Selling Valentine's Gifts
Benzinga Headlines
- How to Profit off Addicts
- The Pepsi Challenge for 8,700 People is to Find a New Job
- How to Profit From Surging Chinese Prices
- Credit Suisse is the Latest Swiss Bank to Disappoint
- Vodafone Misses Quarterly Revenue
TheFlyOnTheWall.com Headlines
- Groupon may have trouble 'regrouping', Barron's says
- Universal Health Services can generate potent returns, Barron's says
- Jim Cramer's "Mad Money"
- Week of 2/22 Fed Balance Sheet to be released at 16:30 ET
- Week of 2/13 Money Supply to be released at 16:30 ET
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
WalletPop Headlines
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
- Why Used Car Bargains Are Getting Harder to Find
- 5 Reasons Facebook Stock May Be a Better Buy Than You Think
- Department Stores Reveal Top Selling Valentine's Gifts
My Portfolios
Track your stocks here!
Find out why more people track their portfolios on AOL Money & Finance then anywhere else.
BloggingStocks Partners
More from AOL Money & Finance
- Business News
- Stock Screener
- Stock Quotes
- Stock Charts
- Banking
- Identity Theft
- DJIA
- Debt Management
- Loans
- Auto Loan
- Mortgages
- Taxes
- Retirement
- Insurance
- Small Business
- Earnings
- Tech News
- Tax Forms
- Tax Deductions
- Tax Credit
- Tax Audit
- Tax Advice
- Stock Ticker
- Stock Brokers
- Resume Builder
- Pig Flu
- Online Tax Filing
- Madoff
- Investing For Retirement
- Income Tax
- Historical Stock Prices
- GOOG
- ETF Investing
- Deals
- DailyFinance
- Crude Oil Prices
- Credit Score Calculator
- Common Tax Filing Mistakes
- AMT
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
The Money Man Behind Rick Santorum: Who Is Foster S. Friess?
Savings Experiment: Snow Removal

